| Journal | Cannabis and cannabinoid research |
| Study Type | Randomized Trial |
| Population | Human participants |
Aromatase inhibitor-associated musculoskeletal syndrome affects nearly two-thirds of breast cancer survivors on hormonal therapy, leading to treatment discontinuation and potentially compromising cancer outcomes. This represents the first randomized trial examining topical cannabis specifically for this prevalent and clinically challenging condition.
This open-label randomized trial enrolled 21 postmenopausal women with stage 1-3 breast cancer experiencing AIMSS, comparing topical CBD versus THC balms applied three times daily to hands for 2 weeks, followed by a 2-week patient-choice extension. The study assessed feasibility, tolerability, and preliminary efficacy using validated rheumatology scales including the Modified Score for Assessment and Quantification of Chronic Rheumatoid Affectations of the Hands (M-SACRAH) and Brief Pain Inventory. While the small sample size limits definitive conclusions about efficacy, the trial design addresses a clinically relevant question with appropriate outcome measures for this specific patient population.
“This pilot study tackles a real clinical problem where conventional treatments often fall short, but the small sample size means I’m still waiting for more robust data before changing my approach to AIMSS management. The focus on topical application is clinically sensible given the localized nature of joint symptoms.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is aromatase inhibitor-associated musculoskeletal syndrome (AIMSS)?
AIMSS affects nearly two-thirds of postmenopausal women taking aromatase inhibitors for hormone receptor-positive breast cancer. It causes joint pain, stiffness, and bone pain that can lead to poor medication adherence and compromised cancer treatment outcomes.
How effective are topical cannabis balms for treating AIMSS symptoms?
This randomized trial showed that both CBD and THC topical balms were feasible and well-tolerated when applied three times daily to hands for 2 weeks. The study measured improvements using validated pain and joint function scales, though specific efficacy results require the complete study data for interpretation.
Is there a difference between CBD and THC balms for joint pain relief?
The study directly compared CBD versus THC balms in a randomized design, with participants able to choose their preferred formulation during a 2-week extension phase. Both formulations appeared tolerable, suggesting either may be viable options for AIMSS management.
Are topical cannabis products safe for breast cancer patients?
The study monitored skin toxicity measures weekly and found the topical balms to be well-tolerated over the 4-week study period. However, breast cancer patients should consult their oncologist before using any cannabis products to ensure no interactions with their cancer treatment regimen.
How should topical cannabis balms be applied for musculoskeletal pain?
Based on this study protocol, the balms were applied three times daily to the affected areas (hands in this case) for optimal results. The frequency and duration of application should be guided by healthcare providers familiar with both cannabis therapeutics and the patient’s overall treatment plan.
